The stock is likely to face significant downward pressure as the company is in financial distress and must raise substantial capital by June 10, 2026 to avoid default. The forbearance agreement suggests creditors anticipate payment difficulties. Traders should monitor for any capital raise announcements and assess dilution risk.
Price Chart
Executive Summary
Karyopharm Therapeutics amended its credit agreement and entered into a forbearance agreement with its lenders and noteholders to defer principal and interest payments until September 2026, contingent on the company raising at least $25 million in equity financing by June 10, 2026. This restructuring indicates severe liquidity pressure and financial distress.
Key Financial Metrics
Key Facts
- Karyopharm entered into a Second Amendment to its Credit and Guaranty Agreement to defer principal and interest payments
- The deferral is contingent on the company raising $25 million in equity financing by June 10, 2026 (the 'Capital Raise Trigger')
- The company also entered into a Forbearance Agreement with 100% of its lenders and noteholders
- The forbearance covers payment defaults on convertible notes due 2028 and 2029
- The company faces substantial doubt regarding its ability to continue as a going concern
- The restructuring allows deferral of a June 10, 2026 principal payment and June 30, 2026 interest payment until September 2026
Financial Impact
Deferral of principal and interest payments worth tens of millions of dollars, contingent on raising $25M in equity
Risk Factors
- Failure to raise $25 million by June 10, 2026 would trigger default and potential bankruptcy
- Any equity raise will be highly dilutive to existing shareholders
- The company faces substantial doubt about its ability to continue as a going concern
- Creditors could resume collection actions if the capital raise fails
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001503802-26-000006 |
| Document: kpti-20260227.htm | 0001503802-26-000006 |
| Document: 0001503802-26-000006-index-headers.html | 0001503802-26-000006 |
| Document: 0001503802-26-000006-index.html | 0001503802-26-000006 |
| Document: 0001503802-26-000006.txt | 0001503802-26-000006 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $1.61 $1.88 | ▼ −16.77% | ▼ −16.99% | $0.8050 (+50.00%) |
Aug 31, 2026 4w ago | 8-K | $2.06 $1.72 | ▼ −16.50% | ▼ −16.36% | $0.8050 (−60.92%) |
Aug 13, 2026 7w ago | 8-K | $1.99 $1.82 | ▲ +8.54% | ▲ +6.58% | $0.8050 (+59.55%) |
Aug 10, 2026 7w ago | Press Release | $1.96 $1.81 | ▼ −7.65% | ▼ −7.61% | $0.8050 (−58.93%) |
Jul 31, 2026 9w ago | 8-K | $1.92 $2.12 | ▲ +10.42% | ▲ +6.91% | $0.8050 (−58.07%) |
Jul 17, 2026 10w ago | 8-K | $7.47 $7.41 | ▼ −0.80% | ▼ −0.38% | $0.8050 (−89.22%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▼ −25.63% | ▼ −24.01% | $0.8050 (+88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access